WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555891

CAS#: 442898-34-2

Description: ML008, also known as NCGC00092410, is a potent and selective inhibitor of glucocerebrosidase with IC50 of 31 nM.

Price and Availability

Size Price Shipping out time Quantity
100mg USD 850 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 2150 2 Weeks
1g USD 2950 2 Weeks
2g USD 5250 2 Weeks
5g USD 8650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-22. Prices are subject to change without notice.

ML008 is in stock.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555891
Name: ML008
CAS#: 442898-34-2
Chemical Formula: C21H27N3O2
Exact Mass: 353.2103
Molecular Weight: 353.466
Elemental Analysis: C, 71.36; H, 7.70; N, 11.89; O, 9.05

Synonym: ML008; ML-008; ML 008; NCGC00092410; NCGC-00092410; NCGC 00092410;

IUPAC/Chemical Name: N-[4-Methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide


InChi Code: InChI=1S/C21H27N3O2/c1-15-13-20(24-9-11-26-12-10-24)23-19-8-7-17(14-18(15)19)22-21(25)16-5-3-2-4-6-16/h7-8,13-14,16H,2-6,9-12H2,1H3,(H,22,25)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. Missense mutations result in reduced enzyme activity that may be due to misfolding, raising the possibility of small-molecule chaperone correction of the defect.


Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, Simeonov A, Goldin E, Auld D, LaMarca ME, Inglese J, Austin CP, Sidransky E. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13192-7. doi: 10.1073/pnas.0705637104. Epub 2007 Aug 1. PMID: 17670938; PMCID: PMC1936979.